Human drug hepatotoxicity: a contemporary clinical perspective

Bibliography

• Ostapowicz G, Fontana RJ, Schiødt FV, et al. U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947-54
   PubMed Web of Science ®Google Scholar
• Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liv Dis 2002;22:145-56
   PubMed Web of Science ®Google Scholar
• Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002;36:451-5
   PubMed Web of Science ®Google Scholar
• Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003;349:474-85
   PubMed Web of Science ®Google Scholar
• Andrade RJ, Robles M, Fernandez-Castaner A, et al. Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J Gastroenterol 2007;13:329-40
   PubMed Web of Science ®Google Scholar
• Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006;354:731-9
   PubMed Web of Science ®Google Scholar
• Abboud G, Kaplowitz N. Drug-induced liver injury. Drug Saf 2007;30:277-94
   PubMed Web of Science ®Google Scholar
• Elinav E, Pinsker G, Safadi R, et al. Association between consumption of Herbalife® nutritional supplements and acute hepatotoxicity. J Hepatol 2007;47:514-20
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Engel A, Fattinger K, et al. Herbal does not mean innocuous: 10 cases of severe hepatotoxicity associated with dietary supplements from Herbalife® products. J Hepatol 2007;47:521-6
   PubMed Web of Science ®Google Scholar
• Adachi M, Saito H, Kobayashi H, et al. Hepatic injury in 12 patients taking the herbal weight loss aids Chaso or Onshido. Ann Intern Med 2003;139:488-92
   PubMed Web of Science ®Google Scholar
• Bonkovsky HL. Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann Intern Med 2006;144:68-71
   PubMed Web of Science ®Google Scholar
• Neff GW, Reddy KR, Durazo FA, et al. Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. J Hepatol 2004;41:1062-4
   PubMed Web of Science ®Google Scholar
• Degott C, Feldmann G, Larrey D, et al. Drug-induced prolonged cholestasis in adults: a histological semiquantitiative study demonstrating progressive ductopenia. Hepatology 1992;15:244-51
   PubMed Web of Science ®Google Scholar
• Desmet VJ. Vanishing bile duct syndrome in drug-induced liver disease. J Hepatol 1997;26(Suppl 1):31-5
   PubMed Web of Science ®Google Scholar
• Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. New York: Appleton-Century-Crofts, 1978
   Google Scholar
• Goodman ZD. Drug hepatotoxicity. Clin Liv Dis 2002;6:381-97
   PubMedGoogle Scholar
• Chang CY, Schiano TD. Review article: drug hepatotoxicity. Alim Pharm Ther 2007;25:1135-51
   PubMed Web of Science ®Google Scholar
• Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. Hepatology 1990;11:272-6
   Web of Science ®Google Scholar
• Danan G, Benichou C. Causality assessment of adverse reactions to drugs–I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-30
   PubMed Web of Science ®Google Scholar
• Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs–II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993;46:1331-6
   PubMed Web of Science ®Google Scholar
• Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997;26:664-9
   PubMed Web of Science ®Google Scholar
• Lucena MI, Camargo R, Andrade RJ, et al. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001;33:123-30
   PubMed Web of Science ®Google Scholar
• Shapiro MA, Lewis JH. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis 2007;11:477-505
   PubMedGoogle Scholar
• Arimone Y, Begaud B, Miremont-Salame G, et al. Agreement of expert judgment in causality assessment of adverse drug reactions. Eur J Clin Pharmacol 2005;61:169-73
   PubMed Web of Science ®Google Scholar
• Aithal GP, Rawlins MD, Day CP. Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ 1999;391:1541
   Google Scholar
• Rochon J, Protiva P, Seeff LB, et al. Reliability of the roussel uclaf causality assessment method for assessing causality in drug-induced liver injury. Hepatology 2008;48:1175-83
   PubMed Web of Science ®Google Scholar
• Brinker AD, Wassel RT, Lyndly J, et al. Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology 2009;49:250-7
   PubMed Web of Science ®Google Scholar
• Drug-induced liver injury network. Available from: http://dilin.dcri.duke.edu/ [Last accessed 1 February 2009]
   Google Scholar
• Hoofnagle JH. Drug-induced liver injury network (DILIN). Hepatology 2004;40:773
   PubMedGoogle Scholar
• Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug-induced liver injury network (DILIN) prospective study. Drug Saf 2009;32:55-68
   PubMed Web of Science ®Google Scholar
• Fountain FF, Tolley E, Chrisman CR, et al. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005;128:116-23
   PubMed Web of Science ®Google Scholar
• Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978;117:991-1001
   PubMed Web of Science ®Google Scholar
• Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999;281:1014-8
   PubMed Web of Science ®Google Scholar
• Gronhagen-Riska C, Hellstrom PE, Froseth B. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Am Rev Resp Dis 1978;118:461-6
   PubMed Web of Science ®Google Scholar
• Dickinson DS, Bailey WC, Hirschowitz BI, et al. Risk factors for isoniazid (INH)-induced liver dysfunction. J Clin Gastroenterol 1981;3:271-9
   PubMed Web of Science ®Google Scholar
• Ungo JR, Jones D, Ashkin D, et al. Antituberculous drug-induced hepatotoxicity. The role of hepatitis C virus and immunodeficiency virus. Am J Respir Crit Care Med 1998;157:1871-6
   PubMed Web of Science ®Google Scholar
• Lee WM, Senior JR. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol Pathol 2005;33:155-64
   PubMed Web of Science ®Google Scholar
• Watkins PB. Idiosyncratic liver injury: challenges and approaches. Toxicol Pathol 2005;33:1-5
   PubMed Web of Science ®Google Scholar
• Mitchell AA, Lacouture PG, Sheehan JE, et al. Adverse drug reactions in children leading to hospital admission. Pediatrics 1988;82:24-9
   PubMed Web of Science ®Google Scholar
• Squires RH, Shneider BL, Bucuvalas J, et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr 2006;148:652-8
   PubMed Web of Science ®Google Scholar
• Huang YS, Su WJ, Huang YH, et al. Genetic polymorphisms of manganese superoxide dismuatase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol 2007;47:128-34
   PubMed Web of Science ®Google Scholar
• Vuilleumier N, Rossier MF, Chiappe A, et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 2006;62:423-9
   PubMedGoogle Scholar
• Lucena MI, Andrade RJ, Martinez C, et al. Glutathione S-transferase M1 and T1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology 2008;48:588-96
   PubMed Web of Science ®Google Scholar
• Tarantino G, Conca P, Basile V, et al. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res 2007;37:410-5
   PubMed Web of Science ®Google Scholar
• Day CP. Nash-related liver failure: one hit too many? Am J Gastroenterol 2002;97:1872-4
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Everhart JE. Diabetes increases the risk of acute hepatic failure. Gastroenterology 2002;122:1822-8
   PubMed Web of Science ®Google Scholar
• Aranzabal L, Casado JL, Moya J, et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2005;40:588-93
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Thomas DL, Chaisson RE, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80
   PubMed Web of Science ®Google Scholar
• Lammert C, Einarsson S, Saha C, et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008;47:2003-9
   PubMed Web of Science ®Google Scholar
• Senior JR. What is idiosyncratic hepatotoxicity? What is it not? Hepatology 2008;47:1813-5
   PubMed Web of Science ®Google Scholar
• Weinshilboum R. Inheritance and drug response. N Engl J Med 2003;348:529-37
   PubMed Web of Science ®Google Scholar
• Matzinger P. Tolerance, danger, and extended family. Annu Rev Immunol 1994;12:991-1045
   PubMed Web of Science ®Google Scholar
• Donaldson PT, Bhatnagar P, Graham J, et al. Flucloxacillin-induced liver injury: the extended MHC 57.1 haplotype as a major risk factor. Hepatology 2008;48(Suppl):396A
   Google Scholar
• Maria VA, Victorino RM. Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury. Gut 1997;41:534-40
   PubMed Web of Science ®Google Scholar
• Usui K, Oda Y, Kubota R, et al. Clinical application of the leukocyte migration test and new diagnostic criteria for identifying causative agents in patients with drug-induced livery injury. Hepatogastroenterology 2007;54:1752-7
   PubMed Web of Science ®Google Scholar
• Davern TJ, James LP, Hinson JA, et al. Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology 2006;130:687-94
   PubMed Web of Science ®Google Scholar
• Fontana RJ. Acute liver failure including acetaminophen overdose. Med Clin N Am 2008;92:761-94
   PubMed Web of Science ®Google Scholar
• Lecoeur S, Andre C, Beaune PH. Tienilic acid-induced autoimmune hepatitis: anti-liver and –kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. Mol Pharmacol 1996;50:326-33
   PubMed Web of Science ®Google Scholar
• Phillips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions – a systematic review. JAMA 2001;286:2270-9
   PubMed Web of Science ®Google Scholar
• Wilke RA, Lin DW, Roden DM, et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 2007;6:904-16
   PubMed Web of Science ®Google Scholar
• Issa AM. Clinical applications of pharmacogenomics to adverse drug reactions. Expert Rev Clin Pharmacol 2008;1:251-60
   PubMedGoogle Scholar
• Alfirevic A, Pirmohamed M. Adverse drug reactions and pharmacogenomics: recent advances. Personalized Med 2008;5:11-23
   PubMed Web of Science ®Google Scholar
• Mendrick DL, Daniels KK. Biomarkers of drug-induced adverse events. Expert Rev Clin Pharmacol 2008;1:81-91
   PubMed Web of Science ®Google Scholar
• Goldschlager N, Epstein NE, Naccarelli G, et al. Practical guidelines for clinicians who treat patients with amiodarone. Practice guidelines subcommittee; North American society of pacing and electrophysiology. Arch Intern Med 2000;160:1741-8
   PubMed Web of Science ®Google Scholar
• Lewis JH, Ranard RC, Caruso A, et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology 1989;9:679-85
   PubMed Web of Science ®Google Scholar
• CDC Core Curriculum on Tuberculosis (2000). Available from: http://www.cdc.gov/tb/pubs/corecurr/Chapter6/Chapter_6_Monitoring.htm [Last accessed 1 February 2009]
   Google Scholar
• Graham DJ, Green L, Senior JR, et al. Troglitazone-induced liver failure: a case study. Am J Med 2003;114:299-306
   PubMed Web of Science ®Google Scholar
• Graham DJ, Drinkard CR, Shatin D, et al. Liver enzyme monitoring in patients treated with troglitazone. JAMA 2001;286:831-3
   PubMed Web of Science ®Google Scholar
• Nathwani RA, Kaplowitz N. Drug hepatotoxicity. Clin Liv Dis 2006;10:207-17
   PubMedGoogle Scholar
• Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 2006;43:618-31
   PubMed Web of Science ®Google Scholar
• Ahmad SR. Adverse drug event monitoring at the food and drug administration. J Gen Int Med 2003;18:57-60
   PubMed Web of Science ®Google Scholar
• Arnaiz JA, Carne X, Riba N, et al. The use of evidence in pharmacovigilance. Case reports as the reference source for drug withdrawals. Eur J Clin Pharmacol 2001;57:89-91
   PubMed Web of Science ®Google Scholar
• Ray WA. Population-based studies of adverse drug effects. N Engl J Med 2003;349:1592-4
   PubMed Web of Science ®Google Scholar
• Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006;29:385-96
   PubMed Web of Science ®Google Scholar
• Chalasani N, Fontana RJ, Bonkovksy HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008;135:1924-34
   PubMed Web of Science ®Google Scholar
• Eudra Vigilance. Available from: http://eudravigilance.emea.europa.eu/human/index.asp [Last accessed 1 February 2009]
   Google Scholar
• Uppsala Monitoring Centre. Available from: http://www.who-umc.org/DynPage.aspx [Last accessed 1 February 2009]
   Google Scholar
• FDA Guidance for Industry – Drug-Induced Liver Injury: premarketing clinical evaluation. Available from: http://www.fda.gov/Cder/guidance/7507dft.htm [Last accessed 11 February 2009]
   Google Scholar
• Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective pravastatin pooling (PPP) project. Circulation 2002;105:2341-6
   PubMed Web of Science ®Google Scholar
• Tolman KG. The liver and lovastatin. Am J Cardiol 2002;89:1374-80
   PubMed Web of Science ®Google Scholar
• Chalsani N, Aljadhey H, Kesterton J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;126:1287-92
   PubMed Web of Science ®Google Scholar
• Lewis JH, Mortensen ME, Zweig S, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled multicenter trial. Hepatology 2007;46:1453-63
   PubMed Web of Science ®Google Scholar
• Russo MW, Galanko JA, Shrestha R, et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004;10:1018-23
   PubMed Web of Science ®Google Scholar